Skip to content

Viking Therapeutics, Inc.: filings

Every Viking Therapeutics, Inc. annual and quarterly report in the SEC record with the published financial measures it tagged, 46 filings, each linked to its SEC index.

Filings with published measures

Each page shows what one filing reported, as tagged in that filing, with the periods it covered. Later filings can restate a value; the company overview shows the latest-filed value per period.

FormFiledFiscal periodMeasuresFactsSEC accession
10-Q2026-07-29fiscal Q2 202631920001193125-26-324219
10-Q2026-04-30fiscal Q1 202631640001193125-26-193315
10-K2026-02-11fiscal FY 202534900001193125-26-046876
10-Q2025-10-23fiscal Q3 202531920001193125-25-247059
10-Q2025-07-23fiscal Q2 202531920000950170-25-097950
10-Q2025-04-24fiscal Q1 202531640000950170-25-058129
10-K2025-02-26fiscal FY 202434890000950170-25-027824
10-Q2024-10-23fiscal Q3 202431920000950170-24-116708
10-Q2024-07-24fiscal Q2 202431920000950170-24-086111
10-Q2024-04-25fiscal Q1 202431640000950170-24-047833
10-K2024-02-07fiscal FY 202334890000950170-24-012322
10-Q2023-10-25fiscal Q3 202332930000950170-23-055259
10-Q2023-07-26fiscal Q2 202332930000950170-23-034773
10-Q2023-04-26fiscal Q1 202332650000950170-23-014883
10-K2023-02-10fiscal FY 202235710001564590-23-001685
10-Q2022-10-26fiscal Q3 202232930001564590-22-035295
10-Q2022-07-27fiscal Q2 202232930001564590-22-026717
10-Q2022-04-27fiscal Q1 202228590001564590-22-016129
10-K2022-02-09fiscal FY 202130620001564590-22-004429
10-Q2021-11-03fiscal Q3 202128800001564590-21-054030
10-Q2021-07-28fiscal Q2 202128800001564590-21-038663
10-Q2021-04-28fiscal Q1 202128600001564590-21-021430
10-K2021-02-17fiscal FY 202030620001564590-21-006406
10-Q2020-10-28fiscal Q3 202028800001564590-20-048398
10-Q2020-07-29fiscal Q2 202028800001564590-20-034329
10-Q2020-04-30fiscal Q1 202028600001564590-20-020233
10-K2020-02-26fiscal FY 201932620001564590-20-006766
10-Q2019-11-05fiscal Q3 201930800001564590-19-040424
10-Q2019-08-01fiscal Q2 201929780001564590-19-028043
10-Q2019-05-02fiscal Q1 201934680001564590-19-015390
10-K2019-03-13fiscal FY 201829600001564590-19-007584
10-Q2018-11-07fiscal Q3 201828820001564590-18-028101
10-Q2018-08-09fiscal Q2 201828770001564590-18-021125
10-Q2018-05-09fiscal Q1 201827560001564590-18-012501
10-K2018-03-07fiscal FY 201725530001564590-18-004757
10-Q2017-11-08fiscal Q3 201721640001564590-17-022829
10-Q2017-08-09fiscal Q2 201721640001564590-17-017021
10-Q2017-05-10fiscal Q1 201721450001564590-17-010332
10-K2017-03-21fiscal FY 201624520001564590-17-004911
10-Q2016-11-10fiscal Q3 201622650001564590-16-028979
10-Q2016-08-11fiscal Q2 201622650001564590-16-024067
10-Q2016-05-10fiscal Q1 201620420001564590-16-018987
10-K2016-03-08fiscal FY 201524480001564590-16-014212
10-Q2015-11-05fiscal Q3 201522620001564590-15-009694
10-Q2015-08-14fiscal Q2 201522600001193125-15-291529
10-Q2015-06-12fiscal Q1 201522450001193125-15-220837

Inspect the source

Entity
Viking Therapeutics, Inc. / CIK 0001607678
Captured
2026-09-20T09:26:18.703Z
SEC response SHA-256
c741f2f24971a4d10aa37b1e293b8d464b95b23c0fecb58db502cd6edd5b0617

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001607678.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))